Published in NMR Biomed on April 01, 2002
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology (2009) 3.30
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. Curr Med Imaging Rev (2009) 2.52
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol (2009) 1.52
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol (2009) 1.39
Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol (2012) 1.38
Amide proton transfer imaging of the breast at 3 T: establishing reproducibility and possible feasibility assessing chemotherapy response. Magn Reson Med (2012) 1.35
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol (2011) 1.25
The promise of dynamic contrast-enhanced imaging in radiation therapy. Semin Radiat Oncol (2011) 1.12
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer (2006) 1.12
Dynamic contrast-enhanced imaging techniques: CT and MRI. Br J Radiol (2011) 1.09
Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology (2011) 1.09
The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer. Semin Oncol (2011) 1.07
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer (2005) 1.07
Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer. J Magn Reson Imaging (2009) 1.06
Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med (2007) 1.05
Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol (2016) 0.99
Robustness of quantitative compressive sensing MRI: the effect of random undersampling patterns on derived parameters for DCE- and DSC-MRI. IEEE Trans Med Imaging (2011) 0.98
Reproducibility of black blood dynamic contrast-enhanced magnetic resonance imaging in aortic plaques of atherosclerotic rabbits. J Magn Reson Imaging (2010) 0.97
Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics (2012) 0.94
Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer (2012) 0.93
Sensitivity of quantitative metrics derived from DCE MRI and a pharmacokinetic model to image quality and acquisition parameters. Acad Radiol (2010) 0.93
Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer. Magn Reson Med (2012) 0.93
Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol (2011) 0.90
DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging (2013) 0.88
A comparison of tumour perfusion assessed by deconvolution-based analysis of dynamic contrast-enhanced CT and MR imaging in patients with squamous cell carcinoma of the upper aerodigestive tract. Eur Radiol (2008) 0.88
Dynamic contrast-enhanced magnetic resonance imaging parameters independent of baseline T10 values. Magn Reson Imaging (2009) 0.87
Assessing reproducibility of diffusion-weighted magnetic resonance imaging studies in a murine model of HER2+ breast cancer. Magn Reson Imaging (2013) 0.86
Multicentre imaging measurements for oncology and in the brain. Br J Radiol (2011) 0.86
Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer. Yonsei Med J (2013) 0.86
Clinical implications of skeletal muscle blood-oxygenation-level-dependent (BOLD) MRI. MAGMA (2012) 0.85
Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer (2005) 0.85
Dynamic contrast-enhanced MRI assessment of hyperemic fractional microvascular blood plasma volume in peripheral arterial disease: initial findings. PLoS One (2012) 0.85
DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker. World J Gastroenterol (2014) 0.85
Reproducibility of magnetic resonance perfusion imaging. PLoS One (2014) 0.83
Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI. Cancer Res (2013) 0.83
Intratumor distribution and test-retest comparisons of physiological parameters quantified by dynamic contrast-enhanced MRI in rat U251 glioma. NMR Biomed (2014) 0.83
Amide proton transfer-weighted imaging of the head and neck at 3 T: a feasibility study on healthy human subjects and patients with head and neck cancer. NMR Biomed (2014) 0.83
Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer. Mol Imaging Biol (2013) 0.82
Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging (2015) 0.81
Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol (2014) 0.81
Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI. Cancer Med (2014) 0.80
Reproducibility of Dynamic Contrast-Enhanced MRI in Renal Cell Carcinoma: A Prospective Analysis on Intra- and Interobserver and Scan-Rescan Performance of Pharmacokinetic Parameters. Medicine (Baltimore) (2015) 0.79
Imaging of HCC-Current State of the Art. Diagnostics (Basel) (2015) 0.79
The role of functional imaging in the era of targeted therapy of renal cell carcinoma. World J Urol (2013) 0.79
Dependence of DCE-MRI biomarker values on analysis algorithm. PLoS One (2015) 0.78
Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion. Cardiovasc Diagn Ther (2014) 0.78
Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls. Transl Oncol (2014) 0.78
A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents. Magn Reson Imaging (2013) 0.78
Sequence design and evaluation of the reproducibility of water-selective diffusion-weighted imaging of the breast at 3 T. NMR Biomed (2014) 0.77
Spectral CT: preliminary studies in the liver cirrhosis. Korean J Radiol (2012) 0.77
Precision analysis of kinetic modelling estimates in dynamic contrast enhanced MRI. MAGMA (2011) 0.77
A linear algorithm of the reference region model for DCE-MRI is robust and relaxes requirements for temporal resolution. Magn Reson Imaging (2012) 0.77
Techniques and applications of dynamic contrast enhanced magnetic resonance imaging in cancer. Conf Proc IEEE Eng Med Biol Soc (2014) 0.76
Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases. BMC Gastroenterol (2013) 0.76
Assessing the accuracy and reproducibility of modality independent elastography in a murine model of breast cancer. J Med Imaging (Bellingham) (2015) 0.76
Imaging in clinical trials. Cancer Imaging (2010) 0.76
DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model-initial experience. MAGMA (2015) 0.75
Computerized breast mass detection using multi-scale Hessian-based analysis for dynamic contrast-enhanced MRI. J Digit Imaging (2014) 0.75
MR Imaging Biomarkers in Oncology Clinical Trials. Magn Reson Imaging Clin N Am (2016) 0.75
Using dynamic contrast-enhanced magnetic resonance imaging data to constrain a positron emission tomography kinetic model: theory and simulations. Int J Biomed Imaging (2013) 0.75
Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response? Br J Radiol (2016) 0.75
Value of Dynamic Contrast-Enhanced MRI to Detect Local Tumor Recurrence in Primary Head and Neck Cancer Patients. Medicine (Baltimore) (2016) 0.75
Added Value of Assessing Adnexal Masses with Advanced MRI Techniques. Biomed Res Int (2015) 0.75
Quantitative Assessment of Liver Function Using Gadoxetate-Enhanced Magnetic Resonance Imaging: Monitoring Transporter-Mediated Processes in Healthy Volunteers. Invest Radiol (2017) 0.75
Intravoxel Incoherent Motion MR Imaging in the Head and Neck: Correlation with Dynamic Contrast-Enhanced MR Imaging and Diffusion-Weighted Imaging. Korean J Radiol (2016) 0.75
Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine. Hepat Med (2010) 0.75
Quantitative Magnetization Transfer Imaging of the Breast at 3.0 T: Reproducibility in Healthy Volunteers. Tomography (2016) 0.75
Bolus arrival time and its effect on tissue characterization with dynamic contrast-enhanced magnetic resonance imaging. J Med Imaging (Bellingham) (2016) 0.75
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol (2016) 0.75
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol (2011) 3.56
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol (2005) 2.59
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol (2003) 2.35
Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol (2008) 2.03
Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2008) 1.95
Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology (2006) 1.91
Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol (2007) 1.80
Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed (2002) 1.80
Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys (2010) 1.64
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol (2009) 1.52
Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag (2004) 1.51
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol (2002) 1.47
Pre-clinical myocardial metabolic alterations in chronic kidney disease. Cardiology (2010) 1.43
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res (2012) 1.42
Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol (2007) 1.41
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. Eur J Cancer (2010) 1.40
Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. BJU Int (2012) 1.39
Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med (2010) 1.38
CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol (2013) 1.34
Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging (2012) 1.33
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med (2009) 1.25
Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review. Radiographics (2009) 1.25
Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys (2010) 1.23
Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys (2007) 1.22
Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review. Skeletal Radiol (2011) 1.21
Bayesian methods for pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans Med Imaging (2006) 1.20
Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol (2006) 1.19
Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol (2012) 1.19
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging (2012) 1.18
Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed (2002) 1.16
Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging (2010) 1.14
Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med (2002) 1.13
Optimization of Rb-82 PET acquisition and reconstruction protocols for myocardial perfusion defect detection. Phys Med Biol (2009) 1.13
Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology (2011) 1.12
Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics (2006) 1.12
Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J Natl Cancer Inst Monogr (2011) 1.12
Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. AJR Am J Roentgenol (2007) 1.08
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol (2006) 1.07
Radiation dosimetry of 82Rb in humans under pharmacologic stress. J Nucl Med (2011) 1.06
Novel oncologic drugs: what they do and how they affect images. Radiographics (2011) 1.05
Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.04
Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech (2009) 1.03
Absolute myocardial flow quantification with (82)Rb PET/CT: comparison of different software packages and methods. Eur J Nucl Med Mol Imaging (2013) 1.03
Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI. J Magn Reson Imaging (2006) 1.02
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application. Phys Med Biol (2013) 1.00
Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med (2011) 1.00
Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys (2004) 0.98
Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging (2010) 0.98
Imaging tumour angiogenesis. Cancer Imaging (2005) 0.96
Dynamic optical breast imaging: a novel technique to detect and characterize tumor vessels. Eur J Radiol (2008) 0.96
Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys (2007) 0.95
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology (2010) 0.94
A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res (2009) 0.94
Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol (2003) 0.94
Can we now agree to use the same definition to measure response according to CA-125? J Clin Oncol (2004) 0.94
The role of functional imaging in colorectal cancer. AJR Am J Roentgenol (2010) 0.93
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res (2010) 0.91
Reproducibility of 2D and 3D fractal analysis techniques for the assessment of spatial heterogeneity of regional blood flow in rectal cancer. Radiology (2012) 0.90
Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys (2010) 0.90
Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol (2011) 0.90